ArticleOpen forum infectious diseases2026
Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Respiratory Syncytial Virus Vaccination as Cardiopulmonary and Cardiovascular Risk Mitigation in Adults with Heart Disease.Journal of clinical medicine · 2026Review
- Country-Level RSV-Related Hospitalisation Rates Among Adults in High-Income Countries From an Ensemble Model Based on Direct Viral Testing Incidence Data.Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) disease burden among adults aged <65 years is not well documented. We aimed to estimate the hospitalization burden of RSV in adults aged 18 to 64 years in high-income countries. Methods: We conducted a systematic review (PROSEPRO: CRD42022377741) to identify studies reporting estimates of RSV hospitalization burden in the study population. For each study included, we followed a 2-step statistical approach to adjust for RSV case underascertainment related to the use of clinical specimen and diagnostic test. Random effects meta-analysis was conducted to estimate RSV hospitalization and mortality burden. We further compared estimates between the 18- to 64-year age group in this study and the ≥65-year age group in our previous study using the same methodology. Results: Based on 8 studies, the adjusted annual RSV-associated hospitalization rate was 48 per 100 000 (95% CI, 31-77) in adults aged 18 to 64 years. According to 12 studies, more than three-quarters of RSV-associated hospitalized adults had at least 1 comorbidity: adults aged 50 to 64 years with asthma, congestive heart failure, chronic obstructive pulmonary disease, coronary artery disease, or diabetes and adults aged 18 to 49 years with congestive heart failure or diabetes had comparable RSV hospitalization rates to those aged ≥65 years without these comorbidities. An overall 6.1% (95% CI, 5.2%-7.1%) of adults aged 18 to 64 years with RSV-associated hospitalization died in the hospital (3 studies). Conclusions: Adults aged 18 to 64 years with certain comorbidities have substantial RSV hospitalization burden comparable to those aged ≥65 years without these comorbidities and could be the additional target populations for RSV vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.